Business Context and Reporting Period
Propanc Biopharma, Inc., a Delaware corporation with its principal executive office in Camberwell, Australia, filed this Form 8-K on May 10, 2024. The report details a material definitive agreement regarding the extension of a debt instrument.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, or margin data. The primary financial metric disclosed relates to a debt obligation:
- Debt Instrument: 10% OID Promissory Note issued on August 15, 2023.
- Original Maturity Date: November 15, 2023.
- New Maturity Date: September 30, 2024.
- Lender: Ionic Ventures, LLC.
Material Changes
The Company entered into a Maturity Extension Agreement with Ionic Ventures, LLC. This agreement retroactively amends the maturity date of the Original Note from November 15, 2023, to September 30, 2024. Both parties acknowledged that no event of default occurred solely due to the Company's failure to pay principal and interest by the original November 15, 2023, deadline. All other terms of the Original Note remain in full force and effect.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or specific risk factors beyond the context of the debt extension. The agreement explicitly addresses the risk of default associated with the missed November 2023 payment date by waiving such default status retroactively.
Investor Verification Checklist
- Verify the total principal amount and accrued interest on the 10% OID Promissory Note, as these figures are not explicitly stated in the summary text.
- Review the full text of the Maturity Extension Agreement (Exhibit 10.1) for any additional covenants, fees, or conditions attached to the extension.
- Confirm the Company's current liquidity position and ability to meet the new September 30, 2024, maturity date.
- Check for any other outstanding debt obligations or potential defaults not mentioned in this specific 8-K filing.